ImmuPharma (GB:IMM) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ImmuPharma PLC, the specialist drug discovery and development company, has successfully sold its entire stake of approximately 9.9 million shares in Incanthera plc, generating gross proceeds of around £1.5 million. Despite this sale, ImmuPharma still holds about 7.3 million warrants in Incanthera, exercisable until 6 September 2024. ImmuPharma is known for developing peptide-based therapeutics, focusing on treatments for autoimmune diseases and anti-infectives, with its leading program P140 targeting Lupus and CIDP.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.